- Alimentiv Inc. announces new scientific advisors leading research in therapies related to the gastrointestinal tract
LONDON, ON, Oct. 13, 2023 /PRNewswire/ -- Alimentiv Inc. ("Alimentiv"), a leading contract research organization focused on gastrointestinal therapies, is pleased to announce the addition of new scientific advisors to its scientific advisory board. The advisors are internationally recognized experts in the design and conduct of clinical research in Inflammatory Bowel Disease. His contributions to the field have been essential in advancing the development of new therapies in IBD and improving patient outcomes.
Dr. and Professor Remo Panaccione is a professor of medicine and director of the Inflammatory Bowel Disease Unit at the University of Calgary, Alberta, Canada. He serves as Dean of Physician Admissions and Director of the IBD Fellowship Program. He holds the Crohn's Colitis Canada Research Chair in Inflammatory Bowel Disease and is an executive member of the IOIBD.
Dr. Panaccione is the 2020 Canadian Crohn's Colitis Outstanding Physician of the Year and is recognized as a 2020-23 Clarivate Research Scholar for being cited in the top 1% of researchers worldwide. He has co-authored more than 350 manuscripts, 20 book chapters, and 625 abstracts, including publications in journals such as the New England Journal of Medicine, Lancet, JAMA, Nature, and Annals of Internal Medicine.
Professor Panaccione's main research interest is the design and implementation of clinical trials. He has been the principal investigator of several studies evaluating the efficacy and safety of new therapeutic agents in patients with IBD.
Bruce Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands is widely recognized for his clinical research on new therapies for inflammatory bowel diseases and has published more than 275 original manuscripts. He was the principal investigator of the landmark studies ACCENT 2, UNIFI and VARSITY, published in the New England Journal of Medicine, and SEAVUE, published in The Lancet. Dr. Bruce Sands serves as a paid consultant to Alimentiv.
"We are committed to leadership in gastrointestinal research and proud to work with industry leaders whose research is critical to the advancement of clinical development programs and treatments for patients living with gastrointestinal-related diseases," said Dr. Gabriela Radulescu, vice president of Medical Research and Development.
About Alimentiv Inc.
Alimentiv is a global contract research organization (CRO) focused on gastroenterology providing clinical trials, central image management, precision medicine and real-world evidence services to the pharmaceutical and biotechnology industries. Headquartered in London, Ontario, Alimentiv employs more than 500 people across operations in Canada, the United States, Europe, Asia-Pacific and Latin America. The organization's unique model combines the efforts of academic researchers and internationally recognized operational experts to deliver integrated solutions to clients. Over the past 20 years, Alimentiv has become a recognized expert in clinical trial design, central image management solutions, outcome measures development, and precision medicine for gastrointestinal drug development. Today, Alimentiv serves more than 50 countries worldwide, collaborates with leading universities and academic institutions around the world, and works with many leading pharmaceutical and biotechnology organizations to bring new and improved treatment options to patients. Alimentiv is committed to investing in medical research and development, focusing on identifying barriers to drug development and finding solutions that advance gastrointestinal research. Research findings are put into practice in an efficient clinical trial methodology for clients that aligns with emerging regulatory standards. In collaboration with leading experts, Alimentiv has pioneered the development, validation and standardization of technologies and outcome measures, shaping the evolving landscape of clinical trials for multiple indications and delivering significant long-term consequences for patients, their treatment and society. For more information visit: www.alimentiv.com
Photo - https://mma.prnewswire.com/media/2245860...Photo - https://mma.prnewswire.com/media/2245861...Logo - https://mma.prnewswire.com/media/ 2245862...
View original content: https://www.prnewswire.com/news-releases/alimentiv-inc-anuncia-nuevos-asesores-cientificos-301956185.html